[go: up one dir, main page]

WO1999061038A1 - Composition possedant un substituant therapeutique et/ou nutritionnellement actif - Google Patents

Composition possedant un substituant therapeutique et/ou nutritionnellement actif Download PDF

Info

Publication number
WO1999061038A1
WO1999061038A1 PCT/US1999/011886 US9911886W WO9961038A1 WO 1999061038 A1 WO1999061038 A1 WO 1999061038A1 US 9911886 W US9911886 W US 9911886W WO 9961038 A1 WO9961038 A1 WO 9961038A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
substituent
beverage
provides
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/011886
Other languages
English (en)
Inventor
R. Douglas Krotzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADAMS FOOD Ltd
Original Assignee
ADAMS FOOD Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADAMS FOOD Ltd filed Critical ADAMS FOOD Ltd
Priority to AU42174/99A priority Critical patent/AU4217499A/en
Publication of WO1999061038A1 publication Critical patent/WO1999061038A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/38—Other non-alcoholic beverages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A23G3/362—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing inorganic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
    • A23G3/368—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing vitamins, antibiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A23L2/56—Flavouring or bittering agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • T is application is a co ⁇ tinuation-i ⁇ -part of U.S. Patent Application Serial Nc.
  • the invention relates to compositions having a nutritionally beneficial substituent and a substituent that stimulates a short and/or long term psychological feedback and to vehicles or devices that accomplish the deiivei ⁇ of the nutritionally beneficial substituent to a recipient.
  • the invention particularly concerns compositions for oral or translingual delivery using beverages, lozenges and the like ?s vehicles to facilitate delivery.
  • the invention additionally concerns the use of transdermal delivery devices (e.g., patches) to accomplish the delivery of such substituent(s).
  • the invention particularly concerns a formulated, substantially alcohol- free beverage for oral consumption having a nutritionally beneficial substituent and a substituent that stimulates psychological feedback and which accomplishes the oral delivery of the nutritionally beneficial substituent.
  • U.S. Patent 5,626,849 (Hastings et al.) concerns a composition for facilitating weight loss.
  • the composition contains chromium, L-carnitine, ⁇ -linolenic acid, (-) hydroxycitric acid, choline, inositol, antioxidants and herbs.
  • U.S. Patent 5,567,424 (Hastings) describes a beverage composition containing herbs, fiber, antioxidants and enzymes.
  • U.S. Patent 5,536,506 (Majeed etai.) ⁇ esc ⁇ bes pipe ⁇ ne-co ⁇ taini ⁇ g compositions.
  • U.S. Patent 5,536,506 (Majeed etai.) ⁇ esc ⁇ bes pipe ⁇ ne-co ⁇ taini ⁇ g compositions.
  • Patent 5,290,505 (Shapira) concerns a nutritional soft d ⁇ nk whose ingredients are said to provide protection from UV damage.
  • the comcosition contains a carotenoid mix and ODtionally, fruit/vegetable juices and/or herbal preparations.
  • U.S. Patent 5,240,732 (Ueda) concerns plant extract-containing beverages supplemented with a sugar-alcohol.
  • U.S. Patents 5,681,569 (Kuznicki et al.) and 4,946,701 (Tsai et al.) both concern beverage compositions that contain green tea extracts.
  • U.S. Patent 5,574,522 (Shan et al.) concerns a powdered concentrate containing one or more pharmacologically active agents for use in hot beverages. The composition may contain caffeine, as well as vitamins and minerals.
  • U.S. Patent 5,571,- 4 41 is directed to nut ⁇ tional supplements comDOSitions that provide psychological feedback.
  • compositions contain vitamins and/or minerals as well as xanthine alkaloids (such as caffeine, etc.) that provide a physiological signal.
  • U.S. Patent 5,114,723 (Stray-Gundersen) concerns hypotonic beverages for supplying physiologically essential electrolytes, nutrient minerals, carbohydrates and other ingredients to a consume r The patent discloses that caffeine may be added to the beverage formulation.
  • U.S Patent 4,992,282 (Mehansho et al.) concerns vitamin and mineral-fortified beverages, which may be supplemented with caffeine.
  • U.S. Patent 4,512,205 (KupDer et al) concerns fruit-flavored carbonated beverages that may be supplemented with caffeine
  • U.S. Patent 4,061,797 U.S. Patent 4,061,797
  • U.S. Patent 4,737,375 (Nakel etal) describes calcium-supplemented beverages.
  • U S. Patent 4,769,244 (Lavie) describes non-hygroscopic water-soluble pulverulent compositions that may be employed to make beverages. Compositions for accomplishing transdermal delivery of pharmaceuticals have also been described (see, for example, U.S. Patents 5,718,914 (Foldva ⁇ ), 5,698,217 (Wilking), 5,721,257 (Baker), 5,683,713 (Blank etal.), and 4,788,189 (Glazer)).
  • the present invention provides an improved composition for accomplishing the delivery of nutritionally beneficial substituents.
  • the present invention additionally provides an improved formulated beverage that provides at least one, and most preferably multiple, short and long term psychological feedback(s) to the consumer SUMMARY OF THE INVENTION:
  • the present invention provides beverages and other compositions that are formulated to provide internal appeal directly to the brain (i.e., brain rewards).
  • the present invention thus relates to a formulated, defined composition having a nutritionally beneficial substituent and a long and/or short term substituent that stimulates psychological feedback and to vehicles or devices that accomplish the delivery of the nutritionally beneficial substituent.
  • Such preferred compositions will typically possess a nutritionally beneficial substituent and both a long term and a short term substituent that stimulates psychological feedback and which accomplishes the delivery of the nutritionally beneficial substituent.
  • Preferred vehicles include oral and/or translingual delivery vehicles, such as beverages, elixirs, lozenges, chewable tablets, and the like, and transdermal delivery devices such as patches, bandages, etc.
  • composition preferably a formulated beverage (most preferably, substantially alcohol-free) for oral human consumption having a defined composition of substituents comprising: at least one nutritionally beneficial substituent (A) selected from the group consisting of:
  • L-cysteine and L-methionine S-adenosylmethionine; green tea; guarana; hops; inositol; iron; kava kava; kombucha tea; kudzu; lobelia; glutamic acid; D-phenylalanine; DL-phenylalanine; L-tyrosine; lecithin; linoleic acid; gamma- linoleic acid; magnesium; milk thistle extract (silymari ⁇ ); niacin; PABA; protopine; puerarin; pyridoxal-5-phosphate; selenium; soluble fiber; St.
  • compositions that additionally contain at least one additional substituent (C) that provides long term psychological feedback and/or at least one additional substituent (D) that provides short term psychological feedback; wherein the substituent (C) that provides the long term psychological feedback is selected from the group consisting of: an anandamide; 5-hydroxytryptophan; 5-fluoro-A-methyltryptamine; 5- fluorotryptophan; 6-fluorotryptophan; tryptophan; allocryptine; caffeine; theophylline; theobromine; California poppy; calcium; chromium picolinate; chromium polynicotinate; chicalote extract; cocoa; chocolate; Damiana ( Tur ⁇ era diffusa); DL-phenylalanine; ephedra; ephedrine; epinephrine; GABA; ginger; ginseng; L-glutamine; green tea; guarana; kava kava; lactuca virosa; L-
  • Johnswort and is present in an amount sufficient to provide a long term feeling of well-being or calmness; and the substituent (D) that provides the short term psychological feedback is selected from the group consisting of: an anandamide; an alcohol enhancer; angelica root; balm; bitter orange (Auranti pericarpium); bogbean; boldo; calamus; California poppy; capsaicum; caraway; cayenne; chamomile; cinchona bark; quinine; chocolate; cinnamon; clove; cocoa; condurango; dandelion; elecampane; GABA; gentian; ginger; ginseng; holy thistle; hops; horehound; dried lemon peel (Ctrl ericardium); mugwcrt; unripe orange; peppermint; quassia; red sage; rosemary; star anise; thyme; tumeric; wormwood; yarrow; and zinc; and is present in an amount sufficient to provide a short term sensation of
  • the invention additionally provides a composition for human consumption, comprising: at least one nutritionally beneficial substituent, the substituent being present in an amount sufficient to provide a nutritional benefit to the human recipient; and at least one additional substituent (C) that provides long term psychological feedback substituent or at least one additional substituent (D) that provides short term psychological feedback; wherein the substituent (C) that provides the long term psychological feedback is selected from the group consisting of: an anandamide; 5-hydroxytryptopha ⁇ ; 5-fluoro-A-methyltryptamine; 5- fiuorotryptophan; 6-fluorotryptophan; tryptophan; allocryptine; caffeine; theophylline; theobromine; California poppy; calcium; chromium picolinate; chromium polynicotinate; chicalote extract; cocoa; chocolate; Damiana (Turnera diffusa); DL-phenylalanine; ephedra; ephedrine; epinephrine; GABA; ginger; gins
  • Johnswort and is present in an amount sufficient to provide a long term feeling of well- being or calmness; and the substituent (D) that provides the short term psychological feedback is selected from the group consisting of: an anandamide; an alcohol enhancer; angelica root; balm; bitter orange (Aurantl pericarpium); bogbean; boldo; calamus; California poppy; capsaicum; caraway; cayenne; chamomile; cinchona bark; quinine; chocolate; cinnamon; clove; cocoa; condurango; dandelion; elecampane; GABA; gentian; ginger; ginseng; holy thistle; hops; horehound; dried lemon peel (CM pericardium); mugwort; unripe orange; peppermint; quassia; red sage; rosemary; star anise; thyme; tumeric; wormwood; yarrow; and zinc; and is present in an amount sufficient to provide a short term sensation of warmth, tingling,
  • the invention additionally provides a method for providing a nutritionally beneficial substituent (A) to a human, comprising administering or providing to the human a composition containing: the nutritionally beneficial substituent (A) in an amount sufficient to provide the nutritional benefit to the human recipient; and at least one additional substituent (C) that provides long term psychological feedback substituent or at least one additional substituent (D) that provides short term psychological feedback; wherein the substituent (C) that provides the long term psychological feedback is selected from the group consisting of: an anandamide; 5-hydroxytryptophan; 5-fluoro-A-methyltryptamine; 5- fluorotryptophan; 6-fluorotryptophan; tryptophan; allocryptine; caffeine; theophylline; theobromine; California poppy; calcium; chromium picolinate; chromium polynicotinate; chicaicte extract; cocoa; chocolate; Damia ⁇ a ( Turnera diffusa); DL-phenylalanine; ephedra; ephedrin
  • Johnswort and is present in an amount sufficient to provide a long term feeling of well- being or calmness; and the substituent (D) that provides the short term psychological feedback is selected from the group consisting of: an anandamide; an alcohol enhancer; angelica root; balm; bitter orange (Auranti pericarpium); bogbean; boldo; calamus; California poppy; capsaicum; caraway; cayenne; chamomile; ⁇ ncho ⁇ a bark; quinine; chocolate; cinnamon; dove; cocoa; condurango; dandelion; elecampane; GABA; gentian; ginger; ginseng; holy thistle; hops; horehound; dried lemon peel (Gt ⁇ pericardium); mug ort; un ⁇ pe orange; peppermint; quassia; red sage; rosemary; star anise; thyme; tume ⁇ c; wormwood; yarrow; and zinc; and is present in an amount sufficient to provide a short term sensation of
  • the invention also provides a composition for human consumption, comprising two, three, four or five nutritionally beneficial substituents (A) selected from the group consisting of adrenochrome semicarbazone; 5-hydroytryptophan; 5-fluoro-A- methyltryptamine; 5-fluoro-tryptopha ⁇ ; 6-fluorotryptophan, tryptophan; acetosalycilic acid; ibuDrophen; acetaminophen; alfalfa; ailocryotine; beta- carotene; calcium; caffeine; theophylline; theobromine, choline, chromium picolinate; chromium polynicotinate, diadzin; diadzein, damiana; turnera diffusa; dandelion; evening primrose oil; foiic aod; GABA, ginger; ginkgo biloba; ginseng; glutathione; cysteine; L-glutamine; gly ⁇ ne
  • the invention also provides a composition for human consumption, comprising two, three, four or five nutritionally beneficial substituents (C) that provide long term psychological feedback, wherein said nutritionally beneficial substituents (C) are selected from the group consisting of an a ⁇ an ⁇ amide; 5-nydroxytryptophan; 5-fIuoro-A-methyitryptam ⁇ ne; 5- fluoratryptophan; 6-fIuorotryptophan; tryptophan; allc ⁇ yptine; caffeine; theoDhylli ⁇ e; theobrom e; California poopv; cal ⁇ um; chromium picolinate; chromium polynicotinate; chicalote extract; cocoa; chocolate; Damiana ( Tumera dlff ⁇ sa); DL-phenylalanine; ephedra; ephed ⁇ ne; epmeph ⁇ ne;
  • GABA GABA
  • ginger ginseng; L-glutamine; green tea; guarana; kava kava; lactuca virosa; L-tyrosine; lobelia; magnesium; maraba; protopi ⁇ e; pseudophed ⁇ ne; pseudoepineoh ⁇ ne; py ⁇ doxal-5-phosphate; red ⁇ ce yeast; serotonin; sucrose; fructose; glucose; high fructose corn syrup; and St. Jonnswort.
  • the invention relates to formulated, defined compositions having a nutritionally beneficial substituent and a long and/or short term substituent that stimulates psychological feedback, oDttonally in comDination with a substituent that provides a traditional psychological feedback.
  • the invention further relates to vehicles cr cevices that accomplish the delivery of the composition to a recipient.
  • the invention concerns such formulated, defined compositions that contain both a short term and a long term substituent that stimulates psychological feedback.
  • Some imcortant conditions e.g., alcohol and drug aouse, etc.
  • imcortant conditions e.g., alcohol and drug aouse, etc.
  • individuals who may suffer from denial, and do not want to admit to the existence of a problem By providing positive psychological feedbacks and multiple benefits common to the class, such individuals can be encouraged to imDrove their nutrition for some of the combination of nutritional benefits, without having to face their psychological problems, and thus, as an unintended consequence, be exposed to the proper nutrition for the long term solution to their major problems.
  • compositions of the present invention are formulated or included in vehicles or devices that accomplish their delivery to recipients, and in particular, to recipient humans.
  • a translingual deliver/ vehicle is one a that accomplishes the delivery of the composition via adsorbtion into the tongue, gums or soft tissues of the oral cavity
  • a vehicle suitable for oral delivery is one that accomplishes the delivery of the composition after ingesti ' on.
  • Oral and translingual/transdermal vehicles indude beverages, lozenges, elixirs, syrups, powders, candies, chewable tabiets, etc.
  • the delivery of the compositions of the present invention is accomplished using a transdermai delivery device.
  • a transdermai delivery device Such devices indude bandages, patches, implants, etc. that accomplish the delivery of substituents via adsorption through the skin.
  • compositions of the present invention are said to be "formulated, defined compositions" by which it is meant that at least two, and preferably all, of their chemical substituents are substantially defined chemically.
  • the compositions of the present invention may contain undefined substituents, such as those found in naturally obtainable plant extracts, etc., in all instances they contain at least two chemically asc ⁇ rtainable substituents that were deliberately added to the composition in predetermined amounts to achieve preselected concentrations.
  • the amounts of such substituents in the compositions of the invention will preferably be determined with consideration of the functional concentration (potency) of the substituent.
  • Beverages for oral administration are the preferred delivery vehicle.
  • the term "beverage” is intended to refer to a liquid composition that is in "single” strength form and is ready to drink. Examples of beverage compositions are well known (see, U.S. Patents 4,737,375 (Nak ⁇ i et al.), 4, 992,252 (Mehans ⁇ o et a!.), 5,583,578 (Heckert et a!.), 5,571,441 (Andcn etal.), each herein incorporated by reference).
  • the invention contemplates the formulation and use of such beverages, as well as the formulation and use of beverage "concentrates.”
  • concentrates include solid materials (capsules, tablets, powders, etc.) or solutions, suspensions, or other liquids that require dilution before attaining their desired final state.
  • Such liquid compositions may be formulated from the dissolution or suspension of solid substituents, or from the mixing of liquid substituents, or both.
  • the liquid compositions of the present invention are intended to be orally provided, as distinguished from intravenous or other means.
  • the beverages of the present invention may be imbibed cooled (as by a refrigerant), or at ambient or elevated temperature (i.e., from about 25 °C to about 180 °C) or at more elevated temperatures (i.e., as a "hot" drink).
  • the beverages of the present invention are imbibed at temperatures below 180 °C.
  • the beverages of the present invention are imbibed at temperatures below 25 °C.
  • the beverages of the present invention are preferably aicohol-free. They thus contain less than about 10% ethanol, more preferably less than about 5% ethanol, and most preferably are alcohol-free (i.e. only a trace amount of ethanol or none at all).
  • the beverages of the present invention may be alcohol-containing beverages (i.e., a beverage having between about 10% and aDout 40% aicohol).
  • the beverages of the present invention may be either carbonated or non-carbonated.
  • carbonated means that the beverage contains both dissolved and dispersed carbon dioxide.
  • Methods of forming carbonated beverages are well known in the art (see, for example, U.S. Patent 4,946,701 (Tsai etal.).
  • the beverages of the present invention will contain from 1.0 to about 4.5 volumes of carbon dioxide.
  • the preferred carbon dioxide beverages contain from about 2 to about 3.5 volumes of carbon dioxide.
  • compositions of the present invention contain at least one substituent selected from a first class of substituents that comprise nutritionally beneficial compounds. Any of a wide array of such substituents may be included in the compositions of the invention.
  • a beverage designed for individuals exhibiting the effects of alconol, or the effects of mood altering prescription or non-prescription drugs may contain substituents that may replace depleted nutrients (such as vitamins, minerals, etc.); serve as antioxi ⁇ ants; improve or repair brain function (e.g., memory, learning, etc.); suppress appetite or alcohol desire; reverse alcohol-related damage; alleviate stress; improve virility; improve or repair liver function, improve or repair immune system responses, alleviate depression; improve or repair blood functions (e.g., oxygen transport, blood sugar level stabilizers, metabolite transport, detoxification, ion balance, etc.).
  • compositions of the present invention contain at least one, and more preferably 2 or more substituents of this first class.
  • Preferred substituents of this first class, their associated function, and their preferred concentrations ..i the compositions of the present invention are described in Table A. In Table A,
  • a substituent is indicated to have multiple associated functions, the same concentration of substituent provides all functions, unless a separate dosage is indicated.
  • a substituent is to be provided at a recited concentration, which is the preferred daily intake amount of the substituent
  • the daily intake amount may be obtained by a single serving, etc.,, or by multiple servings, etc..
  • the daily intake amount will be delivered in three servings, each comp ⁇ sing one third of the total preferred intake amount
  • the amount/day shown is the most preferred amount per day, unless a maximum, more preferred and/or most preferred amount day is indicated. Where no amount/day is provided, the substituent may be provided in any customary or traditional amount/day.
  • compositions of the invention will contain one or more sucn preferred nutritionally beneficial substituents, such more preferred substituents being selected from the group consisting of: Adrenochrome Semicaraazone; 5-hydroytryptocnan or equivalent compounds (e.g.; 5-fluoro-A-methyltryptam ⁇ ne; 5-fluorotryptophan; 6-fluorotryptopnan; tryptoDhan; etc.); Allocrypti ⁇ e; Choline; Diadzin; Diadzein; Damia ⁇ a Turnera Diffusa; Evening Primrose Oil; Giutathione or Giutathione equivalents (e.g.; cysteine; L-glutamine; giycine); Other Giutathione Equivalents: N-acetylcysteine (NAC); L-cysteine - • - L-methionine; S- adenosyimethi
  • compositions of the invention will contain one or more such preferred nutritionally beneficial substituents, such highly preferred substituents being selected from the group consisting of: Adrenochrome Semicarbazone; 5-hydroytryptophan or e ⁇ uivalent compounds (e.g.; 5-fluoro-A-methyltryptamine; 5-fluorotryptophan; 6-fiuorotryptophan; tryptophan; etc.); Allocryptine; Diadzin; Diadzein; Evening Primrose Oil; Other Giutathione Equivalents: N-ac ⁇ tylcysteine (NAC); L-cysteine + L-methionine; S-adenosylmethionine (SAMe); Kudzu; Lobelia; Milk Thistle Extract (Silymarin); Niacin; Protopi ⁇ e; and Puerarin.
  • Adrenochrome Semicarbazone 5-hydroytryptophan or e ⁇ uivalent compounds (e.g.; 5-fluoro-
  • compositions of the invention may contain at least one substituent selected from a second class of substituents that provide a traditional psychological feedback. Any of a wide array of such substituents may be included in the composition. Such substituents will impart a sensory psychological effect to the recipient, such as a pleasant taste, aroma, visual appeal, etc.
  • the compositions of the invention may contain more than one such traditional psychological feedback substituent. Tabie B lists preferred traditional psychological feedback substituents that may be employed in the compositions of the present invention to impart such psychological effect.
  • Sweetener such as calo ⁇ c sweeteners (e.g., fructose, high fructose com syrup, su ⁇ ose, maltose, glucose, lactose, sorbitoi, gaiactose, etc.) or substantially non-caloric sweeteners (e.g., aspartame (and its de ⁇ va ⁇ ves). saccha ⁇ n, L-suqars. cyclamates, etc.)
  • calo ⁇ c sweeteners e.g., fructose, high fructose com syrup, su ⁇ ose, maltose, glucose, lactose, sorbitoi, gaiactose, etc.
  • substantially non-caloric sweeteners e.g., aspartame (and its de ⁇ va ⁇ ves). saccha ⁇ n, L-suqars. cyclamates, etc.
  • Fruit j uice or juice extract such as no ⁇ - ⁇ trus fruit juices or juice extracs (e.g., those obtainable from apple, pineapple, grape, pear, banana, pium, cherry, peach, etc.); oerry fruit juices or juice extracts (sucn as those obtainable from strawberry, blueberry, cranberry, blackberry, etc.); or ⁇ trus fruit juices or juice extracts (such as those obtainaole from orange, grapefruit, lemon, lime, etc.)
  • no ⁇ - ⁇ trus fruit juices or juice extracs e.g., those obtainable from apple, pineapple, grape, pear, banana, pium, cherry, peach, etc.
  • oerry fruit juices or juice extracts sucn as those obtainable from strawberry, blueberry, cranberry, blackberry, etc.
  • ⁇ trus fruit juices or juice extracts such as those obtainaole from orange, grapefruit, lemon, lime, etc.
  • Milk including mammalian milk products such as skim milk and cream, and vegetable milks, such as sov milk.
  • Vegetable j uices or juice extracts (such as those obtainable from carrot, tomato, beets, celerv, etc.) kudzu j 5-hydroxy-trvPt ⁇ Phan
  • Spices and plant extract flavo ⁇ ngs such as cola, ginger, nutmeg, cecos r vanilla, cnccclate. "ur *** , mint, sugar rn aole. heros, etc. ) .
  • Synthetically compounded flavorants or naturally isolated flavorants may be employed as such traditional psychological feedback substtuents.
  • compositions of the present invention may be formulated to contain green tea extract.
  • Green tea helps to control the negative effects of caffeine. See, for example, French patent No. 2,586,532 issued to
  • compositions of the present invention will contain one or more preferred traditional psychological feedback substituents, such more preferred substituents being selected from the group consisting of: Caffeine and caffeine equivalents (e.g.; theophylline; theobromine; related methylxanthines); cola; carbonic acid; phosphoric acid; citric acid; hops; cocoa; chocolate; anandamide; quinine; maiic acid; non-citric fruit juice or juice extract (such as wherein the fruit is grape; apple; cranberry; cherry; peach; etc.); milk; vegetable juice or juice extract (such as wherein the vegetable is carrot; celery; etc.); kudzu; and 5-hydroxy-tryptophan.
  • Caffeine and caffeine equivalents e.g.; theophylline; theobromine; related methylxanthines
  • cola carbonic acid
  • phosphoric acid citric acid
  • hops cocoa
  • chocolate anandamide
  • quinine maiic acid
  • compositions cf the present invention will contain one or more highly preferred traditional psychological feedback substituents, such highiy preferred substituents being selected from the group consisting of: Caffeine and caffeine equivalents (e.g.; theoohylline; theobromine; related methylxanthmes) at a concentration/day of greater than about 55 mg; carbonic acid; phosphoric acd; hops; non-cit ⁇ c fruit juice or fruit juice extract (such as wherein the fruit is grape; apple; cranberry; cherry; peach; etc.); milk, vegetable juice or juice extract (such as wherein the vegetable is carrot; celery; etc.); kudzu; and 5-hydroxy-tryptophan.
  • Caffeine and caffeine equivalents e.g.; theoohylline; theobromine; related methylxanthmes
  • non-cit ⁇ c fruit juice or fruit juice extract such as wherein the fruit is grape; apple; cranberry; cherry; peach; etc.
  • compositions of the invention may contain at least one substituent selected from a third class of substituents that provide long term psychological feedback. Any of a wide array of such substituents may be included in the composition. Such substituents will impart a long term psychological effect to the recipient, such as a feeling of warmth or tingling, of excitement, of tranquillity and well-being, etc.
  • the compositic is of the invention will contain more than one such long term psychologically active substituent Table C lists particularly preferred long term duration psychological feedback substituents that may be employed in the compos.tiors of the present invention to impart a long e 1 "'! psychological effect
  • compositions of the present invention will contain one or more such long term, psychological feedback substituents, such more preferred substituents being selected from the group consisting of: 5-hydroytryptophan or equivalent compounds (e.g.; 5-fluoro-A- methyltryptamine; 5-fluorotryptophan; 6-fIuorotryptophan; tryptophan; etc.); Allocryptine; California Poppy; Chromium (Cr-Picoli ⁇ ate; Cr-Polynicotinate; (Cr amounts increased with amount of Zn present; decreased for amounts of amino acids)); Cocoa; Damiana ( Tur ⁇ era diffusa); D-phenylalanine; Ephedra (especially nevadenis); Ephedri ⁇ e; Epinephrine; GABA; L- giutamine; Green Tea; Kava Kava; Lactuca Virosa; Lobelia; Magnesium; Maraba; Protopine
  • 5-hydroytryptophan or equivalent compounds e.g.; 5-fluor
  • compositions of the present invention will contain one or more such long term psychological feedback substituents, such highly preferred substituents being selected from the group consisting of: 5-hydroytryptophan or equivalent compounds (e.g.; 5- fluoro-A-methyltryptamine; 5-fluorotryptophan; 5-fluorotryptophan; tryptophan; etc.); Allocryptine; California Poppy; Chicalote Extract (without toxic substituents); Cocoa; Damiana (Tumera diffusa); Ephedra nevadenis; Ephed ⁇ ne; Green Tea; Lactuca Virosa; Lobelia; Maraba; Protopine; Pseudophedrine; Pseudoepinephrine and Red Rice Yeast
  • 5-hydroytryptophan or equivalent compounds e.g.; 5- fluoro-A-methyltryptamine; 5-fluorotryptophan; 5-fluorotryptophan; tryptophan; etc.
  • Allocryptine California
  • compositions of the invention may contain at least one substituent selected from a fourth class of substituents that provide short term psychological feedback. Any of a wide array of such substituents may be included in the composition. Such substituents will impart a short term psychological effect to the recipient, such as a feeling of warmth or tingling, of excitement, of tranquillity and well-being, etc. In a preferred embodiment, the compositions of the invention will contain more than one such short term psychologically active substituent.
  • compositions of the invention may contain psychologically active substituents that mediate their respective effects in Doth a short duration (i.e., effect completed within 15 minutes of nutritionally beneficial.) and a long term duration (i.e., effect completed after 15 minutes of nutritionally beneficial).
  • Table D lists preferred short term duration psychological feedback substituents that may be employed in the compositions of the present invention to impart a short term psychological effect.
  • compositions of the present invention will contain one or more preferred short term psychological feedback substituents, such more preferred substituents being selected from the group consisting of: Anandamide; Alcohol Enhancers, Standard Flavorants; Angelica root; Boldo; California Poppy; Capsaicum; Cayenne; GABA; Gentian; Tume ⁇ c; Vitamin K; and Wormwood.
  • preferred substituents being selected from the group consisting of: Anandamide; Alcohol Enhancers, Standard Flavorants; Angelica root; Boldo; California Poppy; Capsaicum; Cayenne; GABA; Gentian; Tume ⁇ c; Vitamin K; and Wormwood.
  • compositions of the present invention will contain one or more highly preferred short term psychological feedback substituents, such highly preferred substituents being selected from the group consisting of: an anandamide; an alcohol enhancer; Angelica root; Boldo; California Poppy; Capsaicum; GABA; Gentian; Tumeric; Vitamin K; and Wormwood.
  • highly preferred substituents being selected from the group consisting of: an anandamide; an alcohol enhancer; Angelica root; Boldo; California Poppy; Capsaicum; GABA; Gentian; Tumeric; Vitamin K; and Wormwood.
  • compositions containing one or more substituents of substituent classes (A) that provide nutritional benefit, (B) that provide traditional psychological feedback, (C) that provide long term psychological feedback, and/or (D) that provide short term psychological feedback.
  • the invention specifically contemplates compositions containing at least one substituent of each of the substituent classes: (A), (B), (C) and (D); (A), (B) and (Q; (A), (B) and (D); (A), (C) and (D); (B), (C) and (D); (A) and (B); (A) and (C); (A) and (D); (B) and (C); (B) and (D); and (C) and (D).
  • T e invention additionally contemplates preferred compositions containing either one or more of the above-recited mere preferred nutritionally beneficial substituents (A) or one or more of the above-recited highly preferred nutritionally beneficial substituents (A), and one or more of the above-recited preferred long term psychological feedback substituents (B), and one or more of the above-recited preferred short term psychological feedback substituents
  • Tne invention additionally contemplates preferred compositions containing one or more of the above-recited preferred nutritionally beneficial substituents (A), and one or more of the above-recited preferred long term psychological feedback substituents (C), and either one or more of the above-recited more preferred short term psychological feedback substituents (D) or one or more of the above-recited highly preferred short term psychological feedback substituents (D).
  • the invention additionally contemplates preferred compositions containing one or more of the above-recited preferred nutritionally beneficial substituents (A), and either one or more of the above-recited more preferred long term psychological feedback substituents (C) or one or more of the above-recited highly preferred long term psychological feedback substitue ⁇ ts (C), and one or more of the above-recited preferred short term psychological feedback substituents (D).
  • the invention further contemplates more preferred compositions containing one or more of the above-recited more preferred nutritionally benefidal substituents (A), and one or more of the aoove-retited preferred long term psychological feedback substituents (C), and one or more of the above-recited more preferred short term psychological feedback substituents (D).
  • the invention further contemplates more preferred compositions containing one or more of the above-recited preferred nutritionally beneficial substituents (A), and one or more of the above-recited more preferred long term psychological feedback substituents (C), and one or more of the above-recited more preferred short term psychological feedback substituents (D).
  • the invention further contemplates highly preferred compositions containing one or more of the above-recited highly preferred nutritionally beneficial substituents (A), and one or more of the above-recited preferred long term psychological feedback substituents (C), and one or more of the above-recited highly preferred short term . psychological feedback substituents (D).
  • the invention further contemplates highly preferred compositions containing one or mere of the above-recited highly preferred nutritionally beneficial substituents (A), and one or more of the above-recited highly preferred long term psychological feedback substituents (C), and one or more of the above-recited preferred short term psychological feedback substituents (D).
  • the invention further contemplates highly preferred compositions containing one or more of the above-recited preferred nutritionally beneficial substituents (A), and one or more of the above-recited highly preferred long term psychological feedback substituents (C), and one or more of the above-recited highly preferred short term psychological feedback substituents (D).
  • the invention further contemplates very highly preferred compositions containing one or more of the above-recited highly preferred nutritionally beneficial substituents (A), and one or more of the above-recited highly preferred long term psychological feedback substituents
  • compositions of the present invention may additionally contain non-pharmacologicai agents such as stomach acid buffering compounds, antacids, fiber, laxatives, muscle relaxants, analgesics, acetaminophens, ibuprophens, topical antibiotics, anti-inflammatory agents, etc.) at non-prescription levels.
  • non-pharmacologicai agents such as stomach acid buffering compounds, antacids, fiber, laxatives, muscle relaxants, analgesics, acetaminophens, ibuprophens, topical antibiotics, anti-inflammatory agents, etc.
  • prescription pharmacological agents such as hormones (e.g., insulin, thyroid hormone, etc.), anti- inflammatory agents, hypertensives, anti-arrhythmias, etc.
  • compositions of the present invention and such prescription pharmacological agents has the salutary effect of confirming or the consumer's perception or recollection that a dosage has been consumed or administered, and as such aids in preventing overdosing and underdosing by individuals who are self administering such pharmacological agents.
  • compositions of the present invention are provided via vehicles for oral or translingual delivery.
  • such vehicles are formulated to contain one or more additional substituents selected from the group consisting of: a xanthine alkaloid (such as a methyixanthine (caffeine, theophylline, theobromine, etc.) obtainable synthetically, or by extraction of plants (e.g. coffee beans, cola nuts, tea plants, etc.); carbonic acid, milk, vegetable juice, fruit juice, phosphoric acid, citric acid, hops, cocoa, chocolate, anandamide, quinine and malic acid.
  • a xanthine alkaloid such as a methyixanthine (caffeine, theophylline, theobromine, etc.
  • a xanthine alkaloid such as a methyixanthine (caffeine, theophylline, theobromine, etc.
  • plants e.g. coffee beans, cola nuts, tea plants, etc.
  • carbonic acid e.g. coffee beans, cola nuts, tea plants,
  • Tne amounts of methyixanthines (and especially caffeine) present in the compositions of the invention are designed to result in the delivery of an amount of such methyixanthines sufficient to impart the desired effect.
  • the composition contain compounds that interact (or sequester) such methylxa ⁇ thines, proportionately larger amounts of methyixanthine will be included in the composition.
  • the composition contain substituents that enhance the desired effect of a methyixanthine, the amount of the methyixanthine in the composition will be proportionately reduced.
  • Serotonin, and its precursors, and substituents that stimulate serotonin production and/or release are also preferred substituents of the compositions of the present invention.
  • compositions of the present invention may comprise dear solutions, or may be suspensions of particulate mate ⁇ al (such as plant pulp or other tissue).
  • particulate mate ⁇ al such as plant pulp or other tissue.
  • beverages When provided as a beverage, such beverages are typically free-flowing and have a viscosity similar to that of water.
  • thickening agents are added to impart greater viscosity to the beverages.
  • the beverages of the present invention are typically dispensed and stored in containers (e.g., cardboard containers, glass or plastic bottles, metal cans, etc.).
  • compositions of the present invention provide a nutritionally beneficial substituent to an individual in a manner accompanied by a reinforcing psychological feedback sensation.
  • the psychological feedback sensation imparts an immediate physiological recognition of the composition (such as a feeling of warmth, or a flush feeling) as well as a long term psychological feedback (such as a counter-depressive effect or a sense of well-being).
  • These feedbacks become psychologically associated with the nutritional benefit and the therapeutic activity of the composition and increase an individual's desire to take or use the composition on a regular basis, and thus serve to ensure that the in ⁇ ivicual obtains a nutritionally beneficial amount of the composition.
  • the compositions of the present invention can be tailored to provide any of a number of desired therapeutic effects.
  • Such effects include blood detoxification; liver repair and detoxification; lessening of a desire to drink alcohol; reversal of alcohol-induced damage; antioxidant activity; alleviating depression, alleviating stress, restoring or improving brain function (such as memory and learning capabilities); suppressing appetite; stabilizing blood sugar levels; improving immune system function and response; etc.
  • compositions can be formulated to contain effective amounts of nutritionally active substituents (such as vitamins, minerals, co- factors, etc.) which build or restore supplies of such substituents damaged by conditions commonly related to each therapy so as to improve the general health of the recipient.
  • nutritionally active substituents such as vitamins, minerals, co- factors, etc.
  • compositions of the present invention are formulated to provice a treatment for the conditions associated with alcoholism and/or the effects of mood alte ⁇ ng prescription or non-prescription drugs (e.g., depressants, narcotics, hallucinogens, stimulants, etc.).
  • mood alte ⁇ ng prescription or non-prescription drugs e.g., depressants, narcotics, hallucinogens, stimulants, etc.
  • compositions, especially beverages are formulated to provide effective amounts of: (1) a liver function reDairant (such as alfalfa, choline, dandelion, gctu kola, .nositol, L-cysteine, L- ethionme, lecithin, milk thistle, nia ⁇ n, selenium, vitamin 31, vitamin D, yellow dock, zinc and or zinc picolinate); (2) a substituent for reversing alcohol- related damage (alfalfa, magnesium, vitamin Bl, vitamin D); (3) a substituent for alleviating stress or depression (such as calcium, choline, folic a ⁇ d, GABA, ginkgo biloba, ginseng, gotu kola, inositol.
  • a liver function reDairant such as alfalfa, choline, dandelion, gctu kola, .nositol, L-cysteine, L- ethi
  • DL-phenylalanine 5-hydroxy-fryptoohan, le ⁇ thin, magnesium, PABA, vitamin B3, vitamin B5, vitamin B12, vitamin C
  • a substituent for reducing the re ⁇ pients desire for alcohol such as daldzin, foiic acid, giutathione, kudzu, l-glutam ⁇ ne, L-methionine, St.
  • a beverage composition is prepared containing:
  • Sodium Benzoate preservative The ingredients were obtained as follows: Glutamme (Twiniab Mega Glutamine); Milk Thistle Seed Extract (Gaia 1:1 (80% alcohol)); St. Johnswort Buds Extract (Gaia 1:1 (80% alcohol)); Vitamin C (Twiniab C-1000 cr/stalline); Vitamin B (Twiniab 3-1-group); Kudzu (Nat re's Herbs, 1 mg daidzm, 556 mg cap); Selenium (Solaray 100 meg); Zinc (Twiniab, Zn gluconate, honey and sweetened); 5-Hydroxy Tryptophan (extract Soiaray 100 mg & St.
  • the beverage composition is clear, and has a light yellow color.
  • the beverage has a light licence flavor similar to the flavor of dilute Galia ⁇ o liqueur.
  • the beverage has the flavor of a soft drink, but maintains a bite and nose suggestive of an alcoholic drink.
  • the mild flavor of the beverage can be masked, if desired, with other flavorants.
  • the beverage has a satisfactory shelf-life.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Non-Alcoholic Beverages (AREA)

Abstract

L'invention porte sur des compositions possédant un substituant ayant une action bienfaisante sur le plan nutritif et un substituant qui stimule une réaction psychologique à court terme et/ou long terme. L'invention porte également sur des excipients et sur des dispositifs permettant d'administrer à un receveur le substituant ayant une action bienfaisante sur le plan nutritif.
PCT/US1999/011886 1998-05-29 1999-05-28 Composition possedant un substituant therapeutique et/ou nutritionnellement actif Ceased WO1999061038A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU42174/99A AU4217499A (en) 1998-05-29 1999-05-28 Composition having therapeutic and/or nutritionally active substituent

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8698498A 1998-05-29 1998-05-29
US09/086,984 1998-05-29
US19943298A 1998-11-25 1998-11-25
US09/199,432 1998-11-25

Publications (1)

Publication Number Publication Date
WO1999061038A1 true WO1999061038A1 (fr) 1999-12-02

Family

ID=26775376

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/011886 Ceased WO1999061038A1 (fr) 1998-05-29 1999-05-28 Composition possedant un substituant therapeutique et/ou nutritionnellement actif

Country Status (2)

Country Link
AU (1) AU4217499A (fr)
WO (1) WO1999061038A1 (fr)

Cited By (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078325A1 (fr) * 1999-06-20 2000-12-28 Lycored Natural Products Industries Ltd. Compositions synergiques contenant du lycopene et de la sylimarine pour le traitement de maladies du foie
NL1016783C2 (nl) * 2000-12-04 2002-06-05 Business Quarters B V Met tryptophaan verrijkte melkdrank.
US6416806B1 (en) * 2000-03-20 2002-07-09 James H. Zhou Herbal caffeine replacement composition and food products incorporating same
WO2002092112A1 (fr) * 2001-05-11 2002-11-21 Holford & Associates Limited Supplement oral
US6503543B1 (en) 2000-05-26 2003-01-07 Craig J. Hudson Tryptophan source from plants and uses therefor
WO2003011054A1 (fr) * 2001-08-02 2003-02-13 Peter Marcinowski Preparation antioxydante complexe
WO2003013495A1 (fr) * 2001-08-08 2003-02-20 Smothers Don L Composition et methode permettant la reduction du stress chez les animaux de boucherie
EP1325747A3 (fr) * 2001-12-20 2003-07-30 Health Pharma S.r.l Supplement diététique pour patients neuropathiques
DE20312929U1 (de) 2003-08-18 2003-10-23 Donhuysen, Sven, 47800 Krefeld Energiegetränk
WO2003101225A1 (fr) * 2002-05-31 2003-12-11 Suomen Ravitsemusinstituutti Oy Composition de boisson et procede de composition d'une boisson
FR2841782A1 (fr) * 2002-07-08 2004-01-09 Clarins Lab Composition cosmetique capable de lutter contre le vieillissement cutane
WO2004020403A2 (fr) 2002-08-27 2004-03-11 Shell William E Composition et procede accroissant et maintenant la production de neurotransmetteurs
WO2004030684A3 (fr) * 2002-10-03 2004-09-23 Herbal Science Llc Produit de kavalactone
WO2005009147A1 (fr) * 2003-07-31 2005-02-03 Shannon Minerals Ltd. Preparation prete a la consommation contenant un principe actif
EP1504671A1 (fr) * 2003-07-30 2005-02-09 Nestec S.A. Délivrance contrôlée de caféine par boissons de café à haute quantité de caféine préparées à partir de poudre soluble
JP2005041853A (ja) * 2003-07-25 2005-02-17 T Langeland Bjorn 特定の金属酵素を刺激する組成物
US6866874B2 (en) 2000-05-26 2005-03-15 Susan P. Hudson Tryptophan source from plants and uses therefor
US6936283B2 (en) * 2003-07-25 2005-08-30 Langeland Bjoern T. Composition for stimulation of specific metallo-enzymes
WO2004089298A3 (fr) * 2003-04-03 2006-03-30 Anlant Thompson Marshall Composition contenant du 5-htp
US7029707B2 (en) 2001-10-03 2006-04-18 Herbalscience, Llc Method of producing a processed kava product having an altered kavalactone distribution and processed kava products produced using the same
US7037524B2 (en) 2001-10-03 2006-05-02 Herbalscience, Llc Oral delivery of a botanical
US7048941B2 (en) * 2001-03-30 2006-05-23 New World Enterprizes, Inc. Chocolate composition as delivery system for nutrients and medications
EP1671550A1 (fr) * 2004-12-15 2006-06-21 Herbalife International, Inc. Compositions pour boisson d'énergie
DE102005006241A1 (de) * 2005-02-10 2006-08-17 Patrick Faber Verwendung von Tryptophan, Nahrungsmittel und Getränk
US7105185B2 (en) 2001-10-03 2006-09-12 Herbalscience, Llc Kavalactone profile
WO2007019685A1 (fr) * 2005-08-12 2007-02-22 Multi Formulations Ltd. Composition de complément diététique comprenant de la caféine, de la taurine et du ginseng
US7279184B2 (en) 2003-10-24 2007-10-09 Herbalscience, Llc Methods and compositions comprising Ilex
US7291352B2 (en) 2001-10-03 2007-11-06 Herbalscience Llc Methods and compositions for oral delivery of Areca and mate' or theobromine
US7294353B2 (en) 2003-10-24 2007-11-13 Herbalscience, Llc Methods and compositions comprising ilex
WO2008040756A1 (fr) * 2006-10-05 2008-04-10 Dsm Ip Assets B.V. Anandamide
EP1605764A4 (fr) * 2003-03-14 2008-07-23 Eurark Llc Composition et procede destines a supprimer l'appetit et l'etat de besoin et a ameliorer l'humeur
EP1581204A4 (fr) * 2002-12-24 2009-01-28 Univ New York Inhibition de melanogenese et de metastase de melanome avec un acide p-aminobenzoique (paba)
US7524815B2 (en) 2001-04-03 2009-04-28 Nestec S.A. Osteoprotegerin in milk
RU2376814C1 (ru) * 2009-04-15 2009-12-27 Олег Иванович Квасенков Способ производства ароматизированного кофейного напитка "битцевский"
US7754700B2 (en) 2006-04-24 2010-07-13 Trager Seymour F Composition and methods for alleviating symptoms of neurotoxicity
US20100209557A1 (en) * 2009-02-14 2010-08-19 O'connor Daniel C Recovery blends for liquid beverages
CN101904351A (zh) * 2010-08-10 2010-12-08 河北三元食品有限公司 一种解酒酸奶及制备方法
US7919125B2 (en) 2001-06-20 2011-04-05 Metaproteomics, Llc Modulation of inflammation by hops fractions and derivatives
WO2011051742A1 (fr) * 2009-10-28 2011-05-05 Modutech S.A. Préparation comprenant des acides aminés et des plantes et son activité dans la détoxification d'alcool
JP2011189143A (ja) * 2001-12-28 2011-09-29 Lahteenmaki Pertti データベース機構を利用して最適な投与量の栄養を生成するための栄養ディスペンサ及び方法
EP2384648A1 (fr) * 2010-05-07 2011-11-09 Deenox SAS Nouvelle composition comprenant des oméga-3 et son utilisation dans la gueule de bois
US8142799B2 (en) * 2001-12-18 2012-03-27 Tamea Rae Sisco High potency clinical anti-craving treatment and method of use
US8142800B1 (en) * 2001-12-18 2012-03-27 Tamea Rae Sisco Oral high potency clinical anti-craving treatment and method of use
EP2505080A1 (fr) * 2011-08-18 2012-10-03 Sybille Pegel Composition de boisson améliorant la santé
US8486457B2 (en) * 2002-10-21 2013-07-16 Metaproteomics, Llc. Compositions that treat or inhibit pathological conditions associated with inflammatory response
RU2498607C2 (ru) * 2008-05-14 2013-11-20 Унилевер Н.В. Замороженные кондитерские продукты
US8642581B1 (en) * 2000-02-11 2014-02-04 Brian D. Halevie-Goldman Compositions and methods for the production of S-adenosylmethionine within the body
CN103829342A (zh) * 2014-03-07 2014-06-04 焦作市恒伟饮品有限公司 功能性保健饮料及其制备方法
CN103843953A (zh) * 2014-03-01 2014-06-11 黄艳英 一种火麻佛手茶
EP1996213A4 (fr) * 2006-03-22 2014-08-20 Targeted Medical Pharma Inc Procédé et compositions pour potentialiser des médicaments à l'aide d'aliments thérapeutiques à base d'acides aminés
US8846115B2 (en) 2001-11-13 2014-09-30 Metaproteomics, Inc. Anti-inflammatory cyclooxygenase inhibitors
CN104188004A (zh) * 2014-07-18 2014-12-10 马鞍山市安康菌业有限公司 一种金针菇橘子汁
CN104223317A (zh) * 2014-09-29 2014-12-24 郭秀珍 一种防腐剂及其制备方法
WO2015136382A1 (fr) * 2014-03-14 2015-09-17 Ipc Intellectual Property Capital Deutschland Gmbh Produit alimentaire coupe-faim contenant de la farine de topinambour
WO2016046795A1 (fr) * 2014-09-26 2016-03-31 Gianluca Mech Complément alimentaire protéiné
US9446100B2 (en) 2015-02-13 2016-09-20 Eastern Vision Limited Dietary supplements and formulations
CN107509842A (zh) * 2017-08-29 2017-12-26 广西双泓商贸有限公司 一种具有保健功能的袋泡茶及其制备方法
CN107624922A (zh) * 2017-10-09 2018-01-26 俞成莲 一种八角养生茶
IT201600111508A1 (it) * 2016-11-07 2018-05-07 Masini Antonio Nutritional Formulation based on Cocoa and specific plant extracts in combination with phosphatidylcholine to support brain functions in the elderly.
WO2021069615A1 (fr) 2019-10-10 2021-04-15 Zobrius Pharma As Composition anti-gueule de bois améliorée, sa préparation et ses utilisations
US11116809B2 (en) * 2017-06-30 2021-09-14 Promend Animal Health, Inc. Biopolymer compositions for the treatment and prevention of liver disease
WO2023183775A3 (fr) * 2022-03-22 2023-11-02 Performance Labs PTE. LTD. Extraction botanique

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4061797A (en) * 1975-08-22 1977-12-06 Hannan Jr Harry Noncarbonated, caffeine-containing fruit and cola flavored beverage
US4612205A (en) * 1985-04-04 1986-09-16 Procter & Gamble Company Carbonated juice beverage with cola taste
US4992282A (en) * 1989-05-08 1991-02-12 The Procter & Gamble Company Stable nutritional vitamin and mineral supplemented beverage
US5431940A (en) * 1994-02-24 1995-07-11 The Procter & Gamble Company Preparation of noncarbonated beverage products with improved microbial stability
US5455235A (en) * 1992-04-10 1995-10-03 Otsuka Pharmaceutical Co., Ltd. Food composition for inhibiting the formation of an intestinal putrefactive product
US5547671A (en) * 1995-09-20 1996-08-20 Duthinh; Phu Anti-intoxication composition
US5641532A (en) * 1995-12-15 1997-06-24 The Procter & Gamble Company Beverages having stable flavor/cloud emulsions in the presence of polyphosphate-containing preservative systems by including gellan gum

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4061797A (en) * 1975-08-22 1977-12-06 Hannan Jr Harry Noncarbonated, caffeine-containing fruit and cola flavored beverage
US4612205A (en) * 1985-04-04 1986-09-16 Procter & Gamble Company Carbonated juice beverage with cola taste
US4992282A (en) * 1989-05-08 1991-02-12 The Procter & Gamble Company Stable nutritional vitamin and mineral supplemented beverage
US5455235A (en) * 1992-04-10 1995-10-03 Otsuka Pharmaceutical Co., Ltd. Food composition for inhibiting the formation of an intestinal putrefactive product
US5431940A (en) * 1994-02-24 1995-07-11 The Procter & Gamble Company Preparation of noncarbonated beverage products with improved microbial stability
US5547671A (en) * 1995-09-20 1996-08-20 Duthinh; Phu Anti-intoxication composition
US5641532A (en) * 1995-12-15 1997-06-24 The Procter & Gamble Company Beverages having stable flavor/cloud emulsions in the presence of polyphosphate-containing preservative systems by including gellan gum

Cited By (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078325A1 (fr) * 1999-06-20 2000-12-28 Lycored Natural Products Industries Ltd. Compositions synergiques contenant du lycopene et de la sylimarine pour le traitement de maladies du foie
US8642581B1 (en) * 2000-02-11 2014-02-04 Brian D. Halevie-Goldman Compositions and methods for the production of S-adenosylmethionine within the body
US6416806B1 (en) * 2000-03-20 2002-07-09 James H. Zhou Herbal caffeine replacement composition and food products incorporating same
US6503543B1 (en) 2000-05-26 2003-01-07 Craig J. Hudson Tryptophan source from plants and uses therefor
US6866874B2 (en) 2000-05-26 2005-03-15 Susan P. Hudson Tryptophan source from plants and uses therefor
US6656473B2 (en) 2000-05-26 2003-12-02 Susan P. Hudson Tryptophan source from plants and uses thereof
NL1016783C2 (nl) * 2000-12-04 2002-06-05 Business Quarters B V Met tryptophaan verrijkte melkdrank.
US7048941B2 (en) * 2001-03-30 2006-05-23 New World Enterprizes, Inc. Chocolate composition as delivery system for nutrients and medications
US7524815B2 (en) 2001-04-03 2009-04-28 Nestec S.A. Osteoprotegerin in milk
WO2002092112A1 (fr) * 2001-05-11 2002-11-21 Holford & Associates Limited Supplement oral
US7919125B2 (en) 2001-06-20 2011-04-05 Metaproteomics, Llc Modulation of inflammation by hops fractions and derivatives
WO2003011054A1 (fr) * 2001-08-02 2003-02-13 Peter Marcinowski Preparation antioxydante complexe
WO2003013495A1 (fr) * 2001-08-08 2003-02-20 Smothers Don L Composition et methode permettant la reduction du stress chez les animaux de boucherie
US7291352B2 (en) 2001-10-03 2007-11-06 Herbalscience Llc Methods and compositions for oral delivery of Areca and mate' or theobromine
US7105185B2 (en) 2001-10-03 2006-09-12 Herbalscience, Llc Kavalactone profile
US7037524B2 (en) 2001-10-03 2006-05-02 Herbalscience, Llc Oral delivery of a botanical
US7029707B2 (en) 2001-10-03 2006-04-18 Herbalscience, Llc Method of producing a processed kava product having an altered kavalactone distribution and processed kava products produced using the same
US7001620B2 (en) 2001-10-03 2006-02-21 Herbal Science, Llc Kavalactone product
US8846115B2 (en) 2001-11-13 2014-09-30 Metaproteomics, Inc. Anti-inflammatory cyclooxygenase inhibitors
US8142799B2 (en) * 2001-12-18 2012-03-27 Tamea Rae Sisco High potency clinical anti-craving treatment and method of use
US8142800B1 (en) * 2001-12-18 2012-03-27 Tamea Rae Sisco Oral high potency clinical anti-craving treatment and method of use
EP1325747A3 (fr) * 2001-12-20 2003-07-30 Health Pharma S.r.l Supplement diététique pour patients neuropathiques
JP2011189143A (ja) * 2001-12-28 2011-09-29 Lahteenmaki Pertti データベース機構を利用して最適な投与量の栄養を生成するための栄養ディスペンサ及び方法
US7638148B2 (en) 2002-05-31 2009-12-29 Suomen Ravitsemusinstituutti Oy Drink composition and a method for composing a drink
WO2003101225A1 (fr) * 2002-05-31 2003-12-11 Suomen Ravitsemusinstituutti Oy Composition de boisson et procede de composition d'une boisson
JP2005527234A (ja) * 2002-05-31 2005-09-15 スオメン・ラビットセムスインスティトゥーティ・オイ 飲料組成物及び飲料の製造方法
FR2841782A1 (fr) * 2002-07-08 2004-01-09 Clarins Lab Composition cosmetique capable de lutter contre le vieillissement cutane
WO2004020403A3 (fr) * 2002-08-27 2004-06-24 William E Shell Composition et procede accroissant et maintenant la production de neurotransmetteurs
WO2004020403A2 (fr) 2002-08-27 2004-03-11 Shell William E Composition et procede accroissant et maintenant la production de neurotransmetteurs
WO2004030684A3 (fr) * 2002-10-03 2004-09-23 Herbal Science Llc Produit de kavalactone
US8486457B2 (en) * 2002-10-21 2013-07-16 Metaproteomics, Llc. Compositions that treat or inhibit pathological conditions associated with inflammatory response
US7691905B2 (en) 2002-12-24 2010-04-06 New York University Inhibition of melanogenesis and melanoma metastasis with p-aminobenzoic acid (PABA)
EP1581204A4 (fr) * 2002-12-24 2009-01-28 Univ New York Inhibition de melanogenese et de metastase de melanome avec un acide p-aminobenzoique (paba)
EP1605764A4 (fr) * 2003-03-14 2008-07-23 Eurark Llc Composition et procede destines a supprimer l'appetit et l'etat de besoin et a ameliorer l'humeur
WO2004089298A3 (fr) * 2003-04-03 2006-03-30 Anlant Thompson Marshall Composition contenant du 5-htp
US6936283B2 (en) * 2003-07-25 2005-08-30 Langeland Bjoern T. Composition for stimulation of specific metallo-enzymes
JP2005041853A (ja) * 2003-07-25 2005-02-17 T Langeland Bjorn 特定の金属酵素を刺激する組成物
WO2005013711A1 (fr) * 2003-07-30 2005-02-17 Nestec S.A. Diffusion regulee de cafeine dans des boissons au cafe hautement cafeinees a base de poudre soluble
EP1504671A1 (fr) * 2003-07-30 2005-02-09 Nestec S.A. Délivrance contrôlée de caféine par boissons de café à haute quantité de caféine préparées à partir de poudre soluble
WO2005009147A1 (fr) * 2003-07-31 2005-02-03 Shannon Minerals Ltd. Preparation prete a la consommation contenant un principe actif
DE20312929U1 (de) 2003-08-18 2003-10-23 Donhuysen, Sven, 47800 Krefeld Energiegetränk
US7279184B2 (en) 2003-10-24 2007-10-09 Herbalscience, Llc Methods and compositions comprising Ilex
US7294353B2 (en) 2003-10-24 2007-11-13 Herbalscience, Llc Methods and compositions comprising ilex
WO2006065255A1 (fr) * 2004-12-15 2006-06-22 Herbalife International, Inc. Formules de boissons energisantes
EP1671550A1 (fr) * 2004-12-15 2006-06-21 Herbalife International, Inc. Compositions pour boisson d'énergie
DE102005006241A1 (de) * 2005-02-10 2006-08-17 Patrick Faber Verwendung von Tryptophan, Nahrungsmittel und Getränk
WO2007019685A1 (fr) * 2005-08-12 2007-02-22 Multi Formulations Ltd. Composition de complément diététique comprenant de la caféine, de la taurine et du ginseng
EP1996213A4 (fr) * 2006-03-22 2014-08-20 Targeted Medical Pharma Inc Procédé et compositions pour potentialiser des médicaments à l'aide d'aliments thérapeutiques à base d'acides aminés
US7754700B2 (en) 2006-04-24 2010-07-13 Trager Seymour F Composition and methods for alleviating symptoms of neurotoxicity
WO2008040756A1 (fr) * 2006-10-05 2008-04-10 Dsm Ip Assets B.V. Anandamide
RU2498607C2 (ru) * 2008-05-14 2013-11-20 Унилевер Н.В. Замороженные кондитерские продукты
US20100209557A1 (en) * 2009-02-14 2010-08-19 O'connor Daniel C Recovery blends for liquid beverages
RU2376814C1 (ru) * 2009-04-15 2009-12-27 Олег Иванович Квасенков Способ производства ароматизированного кофейного напитка "битцевский"
WO2011051742A1 (fr) * 2009-10-28 2011-05-05 Modutech S.A. Préparation comprenant des acides aminés et des plantes et son activité dans la détoxification d'alcool
US9526753B2 (en) 2009-10-28 2016-12-27 Modutech S.A. Preparation comprising amino acids and plants and its activity in the alcohol detoxification
US9192638B2 (en) 2009-10-28 2015-11-24 Modutech S.A. Preparation comprising amino acids and plants and its activity in the alcohol detoxification
WO2011051900A1 (fr) 2009-10-28 2011-05-05 Modutech S.A. Préparation comprenant des acides aminés et des plantes et son activité dans la désintoxication alcoolique
EP2384648A1 (fr) * 2010-05-07 2011-11-09 Deenox SAS Nouvelle composition comprenant des oméga-3 et son utilisation dans la gueule de bois
CN101904351A (zh) * 2010-08-10 2010-12-08 河北三元食品有限公司 一种解酒酸奶及制备方法
EP2505080A1 (fr) * 2011-08-18 2012-10-03 Sybille Pegel Composition de boisson améliorant la santé
CN103843953A (zh) * 2014-03-01 2014-06-11 黄艳英 一种火麻佛手茶
CN103829342A (zh) * 2014-03-07 2014-06-04 焦作市恒伟饮品有限公司 功能性保健饮料及其制备方法
WO2015136382A1 (fr) * 2014-03-14 2015-09-17 Ipc Intellectual Property Capital Deutschland Gmbh Produit alimentaire coupe-faim contenant de la farine de topinambour
CN104188004A (zh) * 2014-07-18 2014-12-10 马鞍山市安康菌业有限公司 一种金针菇橘子汁
WO2016046795A1 (fr) * 2014-09-26 2016-03-31 Gianluca Mech Complément alimentaire protéiné
CN104223317A (zh) * 2014-09-29 2014-12-24 郭秀珍 一种防腐剂及其制备方法
US9446100B2 (en) 2015-02-13 2016-09-20 Eastern Vision Limited Dietary supplements and formulations
US10105419B2 (en) 2015-02-13 2018-10-23 Eastern Vision Limited Dietary supplements and formulations
IT201600111508A1 (it) * 2016-11-07 2018-05-07 Masini Antonio Nutritional Formulation based on Cocoa and specific plant extracts in combination with phosphatidylcholine to support brain functions in the elderly.
US11116809B2 (en) * 2017-06-30 2021-09-14 Promend Animal Health, Inc. Biopolymer compositions for the treatment and prevention of liver disease
CN107509842A (zh) * 2017-08-29 2017-12-26 广西双泓商贸有限公司 一种具有保健功能的袋泡茶及其制备方法
CN107624922A (zh) * 2017-10-09 2018-01-26 俞成莲 一种八角养生茶
WO2021069615A1 (fr) 2019-10-10 2021-04-15 Zobrius Pharma As Composition anti-gueule de bois améliorée, sa préparation et ses utilisations
WO2023183775A3 (fr) * 2022-03-22 2023-11-02 Performance Labs PTE. LTD. Extraction botanique

Also Published As

Publication number Publication date
AU4217499A (en) 1999-12-13

Similar Documents

Publication Publication Date Title
WO1999061038A1 (fr) Composition possedant un substituant therapeutique et/ou nutritionnellement actif
US20010008641A1 (en) Nutritionally active composition for bodybuilding
US11717507B2 (en) Compositions and methods for preventing and recovery from detrimental effects of alcohol consumption
US11134710B2 (en) Cannabinoid emulsion product and process for making the same
AU2010336041A1 (en) Single-use containers and uses thereof
US20060134300A1 (en) Nutritional supplement for caffeine-containing beverages
EP3160590B1 (fr) Solutions de substances nutritives pour l'amélioration de la fonction cognitive
US8507015B2 (en) Composition for countering the effects of alcohol consumption
US20160213624A1 (en) Composition, Commericial Product and Method for Treating Cannabis Toxicity
US20170119836A1 (en) Method of making a liquid composition
US8642095B2 (en) Dietary composition and method of using the same
US20200077678A1 (en) Nutritionally Premium Cola Carbonated Soft Drink - Composition, Method of Preparation and Applications
US20180028473A1 (en) Nutrients solutions
WO2000003679A2 (fr) Composition nutritivement active pour durcir les ongles
US20060094734A1 (en) Composition and method for inducing alertness
US20130248557A1 (en) Dry Powdered Comestibles and Serving Methods Therefor
US20110027192A1 (en) Slim-fit fat burning water
US12156878B1 (en) Compositions and methods for minimizing effects of alcohol intoxication
US20250073201A1 (en) Compositions and methods for treating acute alcohol intake
AU2015234318A1 (en) Single-use containers and uses thereof
Pant et al. Flavoring of Pediatric Nutritional Supplements and Pediatric Compliance: A Perspective
US20140129484A1 (en) Method of marketing protein hydrolysate for high energy sensation
Safe REAL NRG™
DE202011108758U1 (de) Aufbaugetränk
US20130189391A1 (en) Dry Powdered Comestibles

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase